SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain Significant Stake in Cyclacel Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.99% of Cyclacel Pharmaceuticals, Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 1 to their Schedule 13G regarding their beneficial ownership in Cyclacel Pharmaceuticals, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 841,695 shares of Cyclacel Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of the company's common stock.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
• The Reporting Persons have shared voting and shared dispositive power over all 841,695 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cyclacel Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing (Schedule 13G amendment) disclosing beneficial ownership. It contains no positive or negative operational news, financial results, or strategic updates for the issuer, Cyclacel Pharmaceuticals, Inc. The sentiment is neutral as it simply reports a static ownership position.

Positives

• The continued significant stake (9.99%) held by Armistice Capital and Steven Boyd may signal ongoing investor confidence in Cyclacel Pharmaceuticals, Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cyclacel Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• Steven Boyd, as Managing Member of Armistice Capital, LLC, and in his individual capacity, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors. It primarily reflects an investment decision by Armistice Capital.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming their continued ownership and non-control intent.

Key Dates

Keywords

Cyclacel Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Biotechnology, Pharmaceuticals